Yokoyama Shintaro, Miyoshi Hiroaki
Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
Department of Pathology, Kurume University School of Medicine, Kurume, Japan.
J Thorac Dis. 2020 Dec;12(12):7553-7560. doi: 10.21037/jtd-19-3703.
Thymoma is a relatively rare malignancy, which is categorized as thymic epithelial tumor but known as the most common pathology that is developed in the anterior mediastinum. Complete resection is recommended for localized tumors and usually favorable prognosis can be obtained. However, poor survival period has been reported in unresectable cases exhibiting extensive invasion or distant metastasis, as effective chemotherapeutic regimens are restrained. We previously assessed expression of programmed death ligand 1 (PD-L1) and programmed death 1 (PD-1) and discussed their prospective application in the immunotherapy of thymic epithelial tumors. After our publication, additional studies using reliable PD-L1 antibodies, which are currently administered to predict efficacy of PD-1/PD-L1 blockade therapy were performed and further characterized PD-L1 in thymoma. Herein, recent knowledge in relation to the significance of PD-L1 expression in thymoma is reviewed based on recent findings using qualified PD-L1 clones. Most studies coherently found high expression of PD-L1 on the cell membrane and cytoplasm of tumor epithelial cells in accordance with previous reports, which is a predictive marker for effectiveness of anti-PD-1/PD-L1 drugs, even when approved PD-L1 antibodies were employed. On the other hand, PD-L1 expression on tumor infiltrating immune cells remains to be sufficiently determined. High PD-L1 expression can be expected in cases with high grade histological subtypes, such as type B2/B3 thymomas, or those with advanced stages III or IV of the disease. Interestingly, the level of PD-L1 expression was found to be upregulated after chemotherapy compared with that before, which could be explained by immunogenic cell death. The prognostic impact of PD-L1 expression in thymoma might be found only when thymic carcinoma patients were excluded. Furthermore, it also could be identified when we analyzed thymomas completely resected, distinct from biopsy and incompletely resected cases.
胸腺瘤是一种相对罕见的恶性肿瘤,属于胸腺上皮肿瘤,但却是前纵隔最常见的病理类型。对于局限性肿瘤,建议进行完整切除,通常可获得良好的预后。然而,据报道,在出现广泛侵袭或远处转移的不可切除病例中,由于有效的化疗方案受到限制,生存期较差。我们之前评估了程序性死亡配体1(PD-L1)和程序性死亡1(PD-1)的表达,并讨论了它们在胸腺上皮肿瘤免疫治疗中的潜在应用。在我们发表之后,又进行了一些使用可靠的PD-L1抗体的研究,这些抗体目前用于预测PD-1/PD-L1阻断疗法的疗效,并进一步对胸腺瘤中的PD-L1进行了表征。在此,基于使用合格的PD-L1克隆的最新发现,对胸腺瘤中PD-L1表达的意义的最新知识进行综述。大多数研究一致发现,与之前的报道一致,肿瘤上皮细胞的细胞膜和细胞质上高表达PD-L1,这是抗PD-1/PD-L1药物有效性的预测标志物,即使使用了获批的PD-L1抗体。另一方面,肿瘤浸润免疫细胞上的PD-L1表达仍有待充分确定。在高组织学亚型的病例中,如B2/B3型胸腺瘤,或疾病处于III期或IV期晚期的病例中,预计会有高PD-L1表达。有趣的是,与化疗前相比,化疗后PD-L1表达水平上调,这可以用免疫原性细胞死亡来解释。只有排除胸腺癌患者,PD-L1表达在胸腺瘤中的预后影响才可能被发现。此外,当我们分析完全切除的胸腺瘤时,与活检和不完全切除的病例不同,也可以识别出这种影响。